blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1850135

EP1850135 - Method for determining the thrombocyte function and flow conditions [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  09.09.2011
Database last updated on 22.08.2024
Most recent event   Tooltip04.10.2013Lapse of the patent in a contracting state
New state(s): HU		published on 06.11.2013  [2013/45]
Applicant(s)For all designated states
Siemens Healthcare Diagnostics Products GmbH
Görzhäuser Hof Emil-von-Behring-Strasse 76
35041 Marburg / DE
[2008/42]
Former [2007/44]For all designated states
Dade Behring Marburg GmbH
Emil-von-Behring-Strasse 76
35041 Marburg / DE
Inventor(s)01 / Rechner, Andreas, Dr.
Burgweg 5
35043 Marburg / DE
 [2007/44]
Application number, filing date07007504.912.04.2007
[2007/44]
Priority number, dateDE2006102038628.04.2006         Original published format: DE102006020386
[2007/44]
Filing languageDE
Procedural languageDE
PublicationType: A1 Application with search report 
No.:EP1850135
Date:31.10.2007
Language:DE
[2007/44]
Type: B1 Patent specification 
No.:EP1850135
Date:03.11.2010
Language:DE
[2010/44]
Search report(s)(Supplementary) European search report - dispatched on:EP26.07.2007
ClassificationIPC:G01N33/86
[2007/44]
CPC:
G01N33/86 (EP,US)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2007/44]
TitleGerman:Verfahren zur Bestimmung der Thrombozytenfunktion und der Flussbedingungen[2007/44]
English:Method for determining the thrombocyte function and flow conditions[2007/44]
French:Procédé de détermination de la fonction des thrombocytes et des conditions liquides[2007/44]
Examination procedure02.05.2008Examination requested  [2008/24]
03.06.2008Despatch of a communication from the examining division (Time limit: M04)
03.09.2008Reply to a communication from the examining division
20.05.2010Communication of intention to grant the patent
29.06.2010Fee for grant paid
29.06.2010Fee for publishing/printing paid
Opposition(s)04.08.2011No opposition filed within time limit [2011/41]
Fees paidRenewal fee
28.04.2009Renewal fee patent year 03
19.04.2010Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY03.11.2010
CZ03.11.2010
DK03.11.2010
EE03.11.2010
FI03.11.2010
HU03.11.2010
LT03.11.2010
LV03.11.2010
MT03.11.2010
PL03.11.2010
RO03.11.2010
SE03.11.2010
SI03.11.2010
SK03.11.2010
TR03.11.2010
BG03.02.2011
GR04.02.2011
IS03.03.2011
PT03.03.2011
LU12.04.2011
BE30.04.2011
MC30.04.2011
[2013/45]
Former [2013/44]CY03.11.2010
CZ03.11.2010
DK03.11.2010
EE03.11.2010
FI03.11.2010
LT03.11.2010
LV03.11.2010
MT03.11.2010
PL03.11.2010
RO03.11.2010
SE03.11.2010
SI03.11.2010
SK03.11.2010
TR03.11.2010
BG03.02.2011
GR04.02.2011
IS03.03.2011
PT03.03.2011
LU12.04.2011
BE30.04.2011
MC30.04.2011
Former [2013/26]CY03.11.2010
CZ03.11.2010
DK03.11.2010
EE03.11.2010
FI03.11.2010
LT03.11.2010
LV03.11.2010
MT03.11.2010
PL03.11.2010
RO03.11.2010
SE03.11.2010
SI03.11.2010
SK03.11.2010
BG03.02.2011
GR04.02.2011
IS03.03.2011
PT03.03.2011
LU12.04.2011
BE30.04.2011
MC30.04.2011
Former [2013/25]CZ03.11.2010
DK03.11.2010
EE03.11.2010
FI03.11.2010
LT03.11.2010
LV03.11.2010
MT03.11.2010
PL03.11.2010
RO03.11.2010
SE03.11.2010
SI03.11.2010
SK03.11.2010
BG03.02.2011
GR04.02.2011
IS03.03.2011
PT03.03.2011
LU12.04.2011
BE30.04.2011
MC30.04.2011
Former [2012/09]CZ03.11.2010
DK03.11.2010
EE03.11.2010
FI03.11.2010
LT03.11.2010
LV03.11.2010
MT03.11.2010
PL03.11.2010
RO03.11.2010
SE03.11.2010
SI03.11.2010
SK03.11.2010
BG03.02.2011
GR04.02.2011
IS03.03.2011
PT03.03.2011
BE30.04.2011
MC30.04.2011
Former [2012/05]CZ03.11.2010
DK03.11.2010
EE03.11.2010
FI03.11.2010
LT03.11.2010
LV03.11.2010
MT03.11.2010
PL03.11.2010
RO03.11.2010
SE03.11.2010
SI03.11.2010
SK03.11.2010
BG03.02.2011
GR04.02.2011
IS03.03.2011
PT03.03.2011
MC30.04.2011
Former [2012/01]CZ03.11.2010
DK03.11.2010
EE03.11.2010
FI03.11.2010
LT03.11.2010
LV03.11.2010
PL03.11.2010
RO03.11.2010
SE03.11.2010
SI03.11.2010
SK03.11.2010
BG03.02.2011
GR04.02.2011
IS03.03.2011
PT03.03.2011
MC30.04.2011
Former [2011/38]CZ03.11.2010
DK03.11.2010
EE03.11.2010
FI03.11.2010
LT03.11.2010
LV03.11.2010
PL03.11.2010
RO03.11.2010
SE03.11.2010
SI03.11.2010
SK03.11.2010
BG03.02.2011
GR04.02.2011
IS03.03.2011
PT03.03.2011
Former [2011/30]FI03.11.2010
LT03.11.2010
LV03.11.2010
SE03.11.2010
SI03.11.2010
BG03.02.2011
GR04.02.2011
IS03.03.2011
PT03.03.2011
Former [2011/23]FI03.11.2010
LT03.11.2010
LV03.11.2010
IS03.03.2011
Former [2011/19]LT03.11.2010
Documents cited:Search[DX]EP0716744  (DADE INT INC [US]) [DX] 1-8 * abstract * * claims 1,10,11,14 *;
 [Y]WO02074322  (LEUVEN K U RES & DEV [BE], et al) [Y] 4,5 * claims 9,12 *;
 [Y]WO2005007868  (ACCUMETRICS INC [US], et al) [Y] 9,10 * abstract * * figure 3; example 1; claim 1 * * page 1, paragraph 1 * * page 6, paragraph 1 * * page 15, paragraphs 3,4 *;
 [X]  - MISCHKE R ET AL, "Influence of platelet count, acetylsalicylic acid, von Willebrand's Disease, coagulopathies, and haematocrit on results obtained using a platelet function analyser in dogs", VETERINARY JOURNAL, BAILLIERE TINDALL, LONDON,, GB, (200301), vol. 165, no. 1, ISSN 1090-0233, pages 43 - 52, XP002437870 [X] 1-8 * page 44, column 1, paragraph 4 * * abstract *

DOI:   http://dx.doi.org/10.1016/S1090-0233(02)00169-7
 [YX]  - BIN XU ET AL, "Acyclic Analogues of Adenosine Biphosphates as P2Y Receptor Antagonists: Phosphate Substitution Leads to Multiple Pathways of Inhibition of Platelet Aggregation", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, (2002), vol. 45, ISSN 0022-2623, pages 5694 - 5709, XP002285317 [Y] 9,10,12 * abstract * * page 5708, column 2, paragraph 3 * [X] 11

DOI:   http://dx.doi.org/10.1021/jm020173u
 [Y]  - "PROD. NO. M5942 - MRS2395 CELL SIGNALING AND NEUROSCIENCE FIRST P2Y12 RECEPTOR ANTAGONIST AVAILABLE FROM SIGMA-RBI", SIGMA ALDRICH CATALOG, XX, XX, (2002), page 1, XP002437879 [Y] 10,12 * abstract *
 [Y]  - JUDGE H M ET AL, "Incomplete P2Y12 receptor blockade by Clopidogrel is not due to the presence of an internal pool of P2Y12 Receptors", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, BLACKWELL PUBLISHING, OXFORD, GB, (200508), vol. 3, no. Supplement1, ISSN 1538-7933, page P2148, XP002437871 [Y] 10,12 * abstract *
 [Y]  - WIVIOTT STEPHEN D ET AL, "Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial", CIRCULATION, LIPPINCOT WILLIAMS AND WILKINS, BALTIMORE, US, (20050628), vol. 111, no. 25, ISSN 1524-4539, pages 3366 - 3373, XP002437872 [Y] 10 * abstract *

DOI:   http://dx.doi.org/10.1161/CIRCULATIONAHA.104.502815
 [Y]  - KAM P C A ET AL, "The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments", ANAESTHESIA, ACADEMIC PRESS, LONDON, GB, (200301), vol. 58, no. 1, ISSN 0003-2409, pages 28 - 35, XP002437873 [Y] 10 * abstract *

DOI:   http://dx.doi.org/10.1046/j.1365-2044.2003.02960.x
 [Y]  - KOZEK-LANGENECKER S A ET AL, "[Locoregional anesthesia and coagulation inhibitors. Recommendations of the Task Force on Perioperative Coagulation of the Austrian Society for Anesthesiology and Intensive Care Medicine] LOKOREGIONALAESTHESIEN UNTER GERINNUNGSHEMMENDER MEDIKATION. EMPFEHLUNGEN DER ARBEITSGRUPPE PERIOPERATIVE GERINN", ANAESTHESIST, SPRINGER VERLAG, DE, (200505), vol. 54, no. 5, ISSN 0003-2417, pages 476 - 484, XP002437874 [Y] 4,5,8,10 * table 2 *

DOI:   http://dx.doi.org/10.1007/s00101-005-0827-0
 [Y]  - ANDRE PATRICK ET AL, "Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis", CIRCULATION, LIPPINCOT WILLIAMS AND WILKINS, BALTIMORE, US, (20031125), vol. 108, no. 21, ISSN 1524-4539, pages 2697 - 2703, XP002437875 [Y] 8,10 * abstract *

DOI:   http://dx.doi.org/10.1161/01.CIR.0000093279.36628.12
 [Y]  - HOUSTON DAYLE ET AL, "[P-32]2-iodo-N-6-methyl-(N)-methanocarba-2 '-deoxyadenosine-3 ',5 '-bisphosphate ([P-32]MRS2500), a novel radioligand for quantification of native P2Y(1) receptors", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, (200603), vol. 147, no. 5, ISSN 0007-1188, pages 459 - 467, XP002437876 [Y] 12 * abstract *

DOI:   http://dx.doi.org/10.1038/sj.bjp.0706453
 [Y]  - JIN JIANGUO ET AL, "Adenosine diphosphate (ADP)-induced thromboxane A2 generation in human platelets requires coordinated signaling through integrin alphaIIbbeta3 and ADP receptors", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, (20020101), vol. 99, no. 1, ISSN 0006-4971, pages 193 - 198, XP002437877 [Y] 10,12 * abstract * * page 193, column 2, paragraph 1 *

DOI:   http://dx.doi.org/10.1182/blood.V99.1.193
 [X]  - MIYAMOTO K ET AL, "Stimulatory and inhibitory effects of forskolin on adenylate cyclase in rat normal hepatocytes and hepatoma cells.", JOURNAL OF PHARMACOBIO-DYNAMICS FEB 1989, (198902), vol. 12, no. 2, ISSN 0386-846X, pages 87 - 93, XP002441664 [X] 5-7 * abstract *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.